Valeant's $31 Billion of Debt May Be Cut From Ba3 by Moody's

Valeant: Under Investigation by SEC

Valeant Pharmaceuticals International Inc. may have its credit rating cut by Moody’s Investors Service amid concern the company will struggle to reduce debt because its operating performance may be weaker than forecast.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.